New Researches In Treatment Of Rheumatoid Arthritis – Part 2 of 3
The study included more than 6200 rheumatoid arthritis patients who started treatment by taking either tumor necrosis factor inhibitors (TNFi) or non-TNFi biologics. In the TNFi group, the percentages of patients who continued taking their medications were about 82 percent at six months, 68 percent at 12 months and 52 percent at 24 months.
In the non-TNFi group, the percentages for those corresponding leisure periods were about 81 percent, 63 percent and 46 percent, respectively. The usual time to medication discontinuation was 26,5 months in the TNFi group and 20,5 months in the non-TNFi group, the investigators found.